Mode
Text Size
Log in / Sign up
Phase 4 N=45 Treatment

Bilateral Continuous Erector Spinae Blocks for Post-Sternotomy Pain Management

Postoperative Pain

Enrolled (actual)
45
Serious AEs
0.0%
Results posted
Oct 2023
Primary outcome: Primary: Analgesic Requirement — 0.60 (mg/kg)

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Bilateral erector spinae blocks using ropivacaine (Drug)
Age
Pediatric · 2+ yrs
Sex
All
Sponsor
Boston Children's Hospital
Primary completion
Jan 2022

Outcome Measures

OutcomeResultp-value
PRIMARY
Analgesic Requirement
1.34
PRIMARY
Analgesic Requirement
1.34
PRIMARY
Analgesic Requirement
1.34
SECONDARY
Duration of Mechanical Ventilation/Intubation
0.7
SECONDARY
Length of Postoperative ICU Stay
23.3
SECONDARY
Length of Hospital Stay
4.10
SECONDARY
Median Pain Scores
2.92
SECONDARY
Median Pain Scores
2.92
SECONDARY
Median Pain Scores
2.92
SECONDARY
Median Pain Scores
2.92
SECONDARY
Time to First Mobilization
6.75

Summary

To evaluate the efficacy of bilateral continuous erector spinae blocks (BESB) for postoperative analgesia in children and adolescents undergoing cardiac surgical procedures via sternotomy in the Early Recovery After Surgery (ERAS) program in a single arm, open label, interventional study.

Eligibility Criteria

Inclusion Criteria

  • Scheduled as part of the cardiac surgical ERAS program: Patients scheduled for elective surgeries for the following congenital anomalies, or similar: atrial septal defects (all types), partial anomalous pulmonary venous connection (non-obstructed), cor-triatriatum, VSD, partial AV canal, sub-aortic membrane resection, anomalous aortic origin of the coronary arteries, and pulmonary valve/conduit implantation
  • Scheduled for a primary sternotomy.
  • Ages 2 years through 17 years.

Exclusion Criteria

  • Single ventricle physiology.
  • Significant scoliosis or other anatomic contraindications to ESB.
  • Significant intraoperative hemodynamic instability or bleeding, as ascertained by clinicians taking care of the patient.
  • Patients with severe neurodevelopmental delays.
  • Patients with previous chronic pain syndromes.
  • Patients with a history of greater than 24 hours of postoperative or post-procedural opioid treatment at any point in the 2 months prior to surgery.
  • Lack of parental consent and/or child assent.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04567407). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search